InsiderTrades

Form 4 for MNPR Monopar Therapeutics

Accepted 2022-07-01 00:00:00 ET · period of report 2022-06-30 · accession 0001654954-22-009149 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2022-07-01 2022-06-30 MNPR Cittadine Andrew COO F - Tax $2.30 -2,812 5,313 -35% -$6,468
D 2022-07-01 2022-06-30 MNPR Cittadine Andrew COO M - OptEx — +8,125 8,125 New —
D 2022-07-01 2022-06-30 MNPR Cittadine Andrew COO M - OptEx $0.00 -8,125 56.9K -12% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-06-30 F D 2,812 $2.30 5,313 D — —
2 Common Common Stock 2022-06-30 M A 8,125 — 8,125 D — — (F1) Represents shares acquired on vesting and settlement of restricted stock units.
3 Derivative Restricted Stock Units 2022-06-30 M D 8,125 $0.00 56,875 D — · — to — 8,125 Common Stock (F1) Represents shares acquired on vesting and settlement of restricted stock units. (F2) On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.